KYAN Therapeutics

Executive Summary

KYAN Therapeutics is a Singapore-based precision oncology company leveraging its proprietary Optim.AI™ platform to deliver functional drug sensitivity testing. The platform integrates live-cell assays with small-data artificial intelligence to predict optimal single and combination therapies for individual cancer patients. Founded in 2020, the company has scaled to 50-200 employees and operates at the platform stage, positioning itself as a key enabler of personalized cancer treatment. By combining real-time biological testing with AI-driven analytics, KYAN aims to overcome the limitations of genomic-only approaches, addressing tumor heterogeneity and resistance mechanisms. Its functional precision medicine model has the potential to improve patient outcomes while reducing ineffective treatments and healthcare costs. As a private entity with no disclosed funding or valuation, the company remains in a growth phase, focusing on clinical validation and commercial partnerships to demonstrate the clinical utility and scalability of its platform across diverse cancer types. The convergence of AI and functional oncology diagnostics positions KYAN at the forefront of a rapidly evolving precision medicine landscape.

Upcoming Catalysts (preview)

• Q4 2026Clinical validation study results in a major cancer indication60% success
• Q2 2026Strategic partnership with a pharmaceutical or diagnostic company50% success
• Q3 2026Series A or B funding round to support platform expansion70% success